Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study

Abstract The randomized phase 3 CHART trial (NCT03520478) revealed that rezvilutamide (REZ) plus androgen deprivation therapy (ADT) in high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC) significantly enhanced radiographic progression-free and overall survival than bicalutamide (BIC)-...

Full description

Bibliographic Details

Published in:	Signal Transduction and Targeted Therapy
Main Authors:	Hongkai Wang, Shusuan Jiang, Hong Luo, Fangjian Zhou, Dalin He, Lulin Ma, Hongqian Guo, Chaozhao Liang, Tie Chong, Jun Jiang, Zhiwen Chen, Yong Wang, Qing Zou, Ye Tian, Jun Xiao, Jian Huang, Jinchao Chen, Qiang Dong, Xiaoping Zhang, Hanzhong Li, Xinfeng Yang, Jianpo Lian, Wenliang Wang, Dingwei Ye
Format:	Article
Language:	English
Published:	Nature Publishing Group 2024-12-01
Online Access:	https://doi.org/10.1038/s41392-024-02064-z